ZGNX

Zogenix, Inc. [ZGNX] Stock Forecast

Q: What is Zogenix, Inc. stock symbol ?

Zogenix, Inc. is a US stock, located in Emeryville of California and trading under the symbol ZGNX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ZGNX Stock Summary

Earnings have grown 498.77% per last year.

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

Debt-to-Equity ratio of 1.62 is considered moderate, deeper research suggested.

In the News

08:00 30 Nov 2023 ZGNX

Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022

EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Meeting 2022, in-person in Seattle (April 2-7) and held virtually (April 24-26).

10:45 30 Nov 2023 ZGNX

Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -8.89% and 1.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

08:33 30 Nov 2023 ZGNX

Why Zogenix Flew Higher Before Leveling Off This Week

The company attracts a determined suitor from abroad.

10:07 30 Nov 2023 ZGNX

Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist

Which biotech stocks are you watching today?

01:04 30 Nov 2023 ZGNX

Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB

Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.

09:59 30 Nov 2023 ZGNX

Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?

Zogenix (ZGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

11:44 30 Nov 2023 ZGNX

ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today

Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal. The post ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today appeared first on InvestorPlace.

10:18 30 Nov 2023 ZGNX

Why Zogenix Stock Is on Fire Today

A buyout deal is lighting a fire underneath the biotech's shares today.

09:38 30 Nov 2023 ZGNX

Why Zogenix Shares Are Soaring Today

Zogenix Inc (NASDAQ: ZGNX) is trading significantly higher Wednesday morning after the company announced it received a proposal to be acquired by UCB for approximately $1.9 billion. Under terms of the agreement, UCB will offer to purchase all outstanding shares of Zogenix for $26 per share in cash at closing.

07:34 30 Nov 2023 ZGNX

Zogenix Stock (ZGNX): Why The Price Went Up Substantially Today

The stock price of Zogenix, Inc. (NASDAQ: ZGNX) increased by over 60% pre-market today. This is why it happened.

ZGNX Financial details

Company Rating

Neutral

Market Cap

Income

-227.41M

Revenue

81.69M

Book val./share

3.2

Cash/share

5.39

Dividend

Dividend %

Employees

327

Optionable

Shortable

Yes

Earnings

28 Feb 2022

P/E

-6.3

Forward P/E

PEG

-14.45

P/S

P/B

P/C

4.95

P/FCF

Quick Ratio

3.19

Current Ratio

3.63

Debt / Equity

1.62

LT Debt / Equity

0.93

EPS (TTM)

-4.07

EPS next Y

EPS next Q

EPS this Y

8.72%

EPS next Y

EPS next 5Y

EPS last 5Y

-1.83%

Revenue last 5Y

52.76%

Revenue Q/Q

17.68%

EPS Q/Q

-5.77%

SMA20

SMA50

SMA100

Inst Own

105.43%

Inst Trans

1.03%

ROA

-49%

ROE

-83%

ROC

-0.6%

Gross Margin

94%

Oper. Margin

-274%

Profit Margin

-278%

Payout

Shs Outstand

56.23M

Shs Float

48.51M

Target Price

52W Range

26.51-26.9

52W High

+2.62%

52W Low

+2.62%

RSI

Rel Volume

3.63

Avg Volume

3.1M

Volume

11.25M

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

0.899114

Volatility

0%, 0%

Prev Close

Price

26.68

Change

0.64%

ZGNX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.36	0	0.08	0.25	1.52
Net income per share	-4.65	-3.27	-9.74	-3.9	-4.24
Operating cash flow per share	-2.78	-2.95	-2.59	-3.12	-3.45
Free cash flow per share	-2.78	-2.97	-2.81	-3.33	-3.45
Cash per share	10.75	13.57	5.83	9.41	5.62
Book value per share	11.04	13.8	5.69	6.89	3.33
Tangible book value per share	7.06	10.93	3.17	4.93	1.53
Share holders equity per share	11.04	13.8	5.69	6.89	3.33
Interest debt per share	0.1	0	0.03	2.88	3.42
Market cap	1.09B	1.38B	2.25B	1.07B	872.43M
Enterprise value	799.9M	1.31B	2.2B	1.06B	939.73M
P/E ratio	-8.62	-11.15	-5.35	-5.13	-3.84
Price to sales ratio	111.33	0	615.47	78.66	10.68
POCF ratio	-14.41	-12.37	-20.13	-6.41	-4.71
PFCF ratio	-14.4	-12.26	-18.55	-6	-4.71
P/B Ratio	3.63	2.64	9.16	2.9	4.87
PTB ratio	3.63	2.64	9.16	2.9	4.87
EV to sales	81.45	0	601.77	77.5	11.5
Enterprise value over EBITDA	-6.46	-10.61	-5.25	-4.86	-4.64
EV to operating cash flow	-10.54	-11.76	-19.68	-6.31	-5.07
EV to free cash flow	-10.53	-11.65	-18.14	-5.91	-5.07
Earnings yield	-0.12	-0.09	-0.19	-0.2	-0.26
Free cash flow yield	-0.07	-0.08	-0.05	-0.17	-0.21
Debt to equity	0.39	0.24	0.69	0.76	1.62
Debt to assets	0.28	0.19	0.41	0.43	0.62
Net debt to EBITDA	2.37	0.55	0.12	0.07	-0.33
Current ratio	14.52	9.13	3.01	6.31	3.63
Interest coverage	-45.36	-23.53K	-214.91K	-65.9	-14.67
Income quality	0.6	0.9	0.27	0.8	0.81
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.15	0	9.22	7.3	0
Research and developement to revenue	6.87	0	31.7	10.12	1.75
Intangibles to total assets	0.26	0.17	0.26	0.16	0.21
Capex to operating cash flow	0	0.01	0.09	0.07	0
Capex to revenue	-0.01	0	-2.6	-0.83	0
Capex to depreciation	-0.18	-6.57	-7.49	-2.08	-0.01
Stock based compensation to revenue	0.63	0	5.82	2.14	0.43
Graham number	33.98	31.86	35.31	24.58	17.82
ROIC	0.69	-0.28	-1.52	-0.75	-0.92
Return on tangible assets	-0.41	-0.23	-1.37	-0.38	-0.61
Graham Net	6.5	10.26	1.9	4.23	0.42
Working capital	283.72M	474.36M	191.85M	439.46M	256.87M
Tangible asset value	192.79M	414.07M	136.33M	264.88M	82.06M
Net current asset value	188.61M	407.2M	118.05M	240.71M	65.05M
Invested capital	0	0	0.01	0.41	0.94
Average receivables	6.29M	0	0	1.91M	6.98M
Average payables	3.95M	5.67M	7.98M	9.96M	16.97M
Average inventory	3.52M	0	0	513K	3.26M
Days sales outstanding	0	0	0	102.31	45.3
Days payables outstanding	114.17	0	0	8.04K	1.66K
Days of inventory on hand	0	0	0	690.94	414.68
Receivables turnover	0	0	0	3.57	8.06
Payables turnover	3.2	0	0	0.05	0.22
Inventory turnover	0	0	0	0.53	0.88
ROE	-0.42	-0.24	-1.71	-0.57	-1.27
Capex per share	0	-0.03	-0.22	-0.21	0

Quarterly Fundamentals Overview

Last date of statement is 2021-12-31 for Q4

Metric	2020-12-31	2021-03-31	2021-06-30	2021-09-30	2021-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.15	0.25	0.34	0.4	0.48
Net income per share	-1.26	-1	-1.05	-1.04	-0.98
Operating cash flow per share	-0.69	-0.97	-0.77	-0.85	-0.73
Free cash flow per share	-0.8	-0.97	-0.77	-0.85	-0.73
Cash per share	9.07	7.81	7.04	6.14	5.39
Book value per share	6.64	5.76	4.89	4.01	3.2
Tangible book value per share	4.76	3.92	3.08	2.24	1.47
Share holders equity per share	6.64	5.76	4.89	4.01	3.2
Interest debt per share	2.78	2.99	3.02	3.05	3.08
Market cap	1.11B	1.09B	964.85M	849.2M	910.05M
Enterprise value	1.1B	1.16B	990.68M	909.64M	977.35M
P/E ratio	-3.97	-4.89	-4.1	-3.66	-4.15
Price to sales ratio	130.94	79.53	51.35	37.56	34.2
POCF ratio	-29.18	-20.21	-22.47	-17.92	-22.13
PFCF ratio	-25.09	-20.17	-22.47	-17.92	-22.13
P/B Ratio	3.01	3.39	3.54	3.79	5.08
PTB ratio	3.01	3.39	3.54	3.79	5.08
EV to sales	129.07	85.13	52.73	40.23	36.73
Enterprise value over EBITDA	-17.14	-23.52	-18.78	-17.56	-20.15
EV to operating cash flow	-28.76	-21.63	-23.08	-19.2	-23.76
EV to free cash flow	-24.73	-21.59	-23.08	-19.2	-23.76
Earnings yield	-0.06	-0.05	-0.06	-0.07	-0.06
Free cash flow yield	-0.04	-0.05	-0.04	-0.06	-0.05
Debt to equity	0.76	0.81	0.98	1.22	1.62
Debt to assets	0.43	0.45	0.49	0.55	0.62
Net debt to EBITDA	0.25	-1.55	-0.49	-1.17	-1.39
Current ratio	6.31	7.77	6.01	4.79	3.63
Interest coverage	-18.03	-13.86	-14.63	-14	-16.14
Income quality	0.54	0.97	0.73	0.82	0.75
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	3.44	0	0	0	0
Research and developement to revenue	4.23	2.26	1.95	1.47	1.57
Intangibles to total assets	0.16	0.18	0.19	0.2	0.21
Capex to operating cash flow	0.16	0	0	0	0
Capex to revenue	-0.73	-0.01	0	0	0
Capex to depreciation	-2.64	-0.04	0	0	0
Stock based compensation to revenue	0.86	0.59	0.51	0.36	0.36
Graham number	13.72	11.37	10.77	9.68	8.39
ROIC	-0.22	-0.13	-0.22	-0.2	-0.26
Return on tangible assets	-0.13	-0.12	-0.13	-0.15	-0.15
Graham Net	4.08	3.25	2.39	1.42	0.4
Working capital	439.46M	396.2M	347.05M	297.04M	256.87M
Tangible asset value	264.88M	218.46M	172.01M	125.42M	82.06M
Net current asset value	240.71M	195.05M	149.18M	102.77M	65.05M
Invested capital	0.41	0.51	0.6	0.74	0.94
Average receivables	2.57M	4.97M	6.91M	8.59M	9.81M
Average payables	9.58M	11.95M	11.4M	11.47M	17.06M
Average inventory	1.02M	1.68M	2.62M	3.21M	4.5M
Days sales outstanding	40.48	40.24	36.89	37.76	34.29
Days payables outstanding	2.67K	1.59K	797.7	842.48	1.21K
Days of inventory on hand	229.7	309.41	215.28	243.57	301.02
Receivables turnover	2.22	2.24	2.44	2.38	2.62
Payables turnover	0.03	0.06	0.11	0.11	0.07
Inventory turnover	0.39	0.29	0.42	0.37	0.3
ROE	-0.19	-0.17	-0.22	-0.26	-0.31
Capex per share	-0.11	0	0	0	0

ZGNX Frequently Asked Questions

What is Zogenix, Inc. stock symbol ?

Zogenix, Inc. is a US stock , located in Emeryville of California and trading under the symbol ZGNX

Is Zogenix, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $26. The lowest prediction is $26 and the highest is $26

What is ZGNX stock prediction ?

What is Zogenix, Inc. stock quote today ?

Zogenix, Inc. stock price is $26.68 today.

Is Zogenix, Inc. stock public?

Yes, Zogenix, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 3.1M
Employee 327
CEO Dr. Stephen Farr
Headquarters Emeryville,CALIFORNIA,US
IPO Date 2010-11-23
Website https://www.zogenix.com

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.